A proprietary amla extract from Sabinsa offered significant support for blood sugar and cholesterol in recent study
A recent study found that a proprietary amla ingredient from Sabinsa, called Saberry, supported blood sugar parameters in diabetic subjects.
Photo © AdobeStock.com/ 6okean
A recent study1 found that a proprietary amla ingredient from Sabinsa (East Windsor, NJ), called Saberry, supported blood sugar parameters in diabetic subjects. In the 90-day, multicentric randomized open label trial, 124 newly diagnosed diabetic subjects between the ages of 30 and 65 with diabetic dyslipidemia were randomized to receive either 1 g per day of the amla extract, 2 g per day of the amla extract, or 500 mg per day of metformin for 90 days.
Results showed that all the treatment groups saw significant reductions in fasting blood sugar and postprandial blood sugar (FBS and PPBS), hemoglobin A1c (HbA1c) and lipid levels. Subjects receiving 2 g per day of the amla extract had significantly higher reductions of FBS, PPBS and HbA1c, compared to metformin and 1 g per day of the amla extract. Reductions in LDL and total cholesterol were also significantly higher among those taking 2 g per day of the amla extract compared to 1 g per day of amla, and comparable to the metformin group.
Reference
- Majeed, M.; Mundkur, L.; Paulose, S.; Nagabhushanam, K. Novel Emblica officinalis Extract Containing β-glucogallin vs. Metformin: a Randomized, Open-Label, Comparative Efficacy Study in Newly Diagnosed Type 2 Diabetes Mellitus Patients with Dyslipidemia. Food & Function. 2022. 13: 9523-9531. DOI: 10.1039/D2FO01862D
